We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Liquid Tissue® Patent Licensed for Amyloidosis Proteomic Assay
News

Liquid Tissue® Patent Licensed for Amyloidosis Proteomic Assay

Liquid Tissue® Patent Licensed for Amyloidosis Proteomic Assay
News

Liquid Tissue® Patent Licensed for Amyloidosis Proteomic Assay

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Liquid Tissue® Patent Licensed for Amyloidosis Proteomic Assay"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Expression Pathology has announced Mayo Clinic has licensed non-exclusive rights to Expression Pathology’s Liquid Tissue® patent for use in diagnosis of systemic amyloidosis in formalin-fixed tissue.

The patented Liquid Tissue® methodology enables solubilization of proteins for mass spectrometric analysis of formalin-fixed paraffin-embedded (FFPE) tissue, the standard form of preserved patient tissue used in clinical pathology testing worldwide.

Mayo Clinic has applied the technology to develop a specific and sensitive mass spectrometry based method for diagnosis and classification of amyloidosis in routine biopsy specimens, in a format that is readily applicable in a clinical setting. This test is being offered to patients worldwide through Mayo Medical Laboratories, Mayo Clinic’s reference laboratory.

With 50,000 diagnosed cases every year worldwide amyloidosis can be a localized or systemic disease, characterized by organ function impairment, sometimes as severe as cardiac and/or renal failure. Subtyping of cases is critical as management of the disease differs radically, from drug therapies to major organ transplants.

The new Liquid Tissue-based method aids in treatment decisions as it exhibits sensitivity and specificity than the traditional IHC based classification. In an early case study of 56 FFPE cardiac biopsies involving amyloidosis immunohistochemistry was diagnostic in 19/52 cases and equivocal in 33/52 cases (4 cases no IHC). The mass spectrometry-based Liquid Tissue method identified the amyloidosis type in 53 of 56 cases studied.

“Detailed mass spectrometry analysis of proteins related to specific disease conditions in FFPE tissue is opening huge opportunities in personalized medicine to relate those measurements to patient treatment decisions” said Casey Eitner, President and CEO of Expression Pathology. “We are delighted that Mayo Clinic has applied our Liquid Tissue® methodology to solve a difficult medical problem.”

Financial terms of the agreement were not disclosed.
Advertisement